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Abstract
Objective: The objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease
activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis.
Methods: Randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients were eligible if they had axial
spondyloarthritis and had been in clinical remission for ≥ 6months with any available TNFi (adalimumab, etanercept,
infliximab, golimumab) at the dose recommended by product labelling. Patients were randomized by automated central
allocation to continue the same TNFi dose schedule, or to reduce the dose by roughly half according to the protocol. The
main outcome was the proportion of subjects with LDA after 1 year. Serious adverse reactions or infections were recorded.
Results: The trial stopped due to end of the funding period, after 126 patients were randomized; 113 patients (84.1% male,
mean age (SD) 45.6 (13.0) years) were included in the main per-protocol subset. Non-inferiority was concluded for LDA at 1
year (47/55 (83.8%) patients in the full-dose and 48/58 (81.3%) patients in the reduced-dose arm, adjusted difference (95%
CI) − 2.5% (− 16.6% to 11.7%)). Serious adverse reactions or infections were reported in 7/62 patients (11.3%) assigned to full
dose and 2/61 patients (3.3%) assigned to reduced dose (p value = 0.164).
Conclusion: In patients with ankylosing spondylitis in clinical remission for at least 6months, dose reduction is non-inferior
to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses.
Trial registration: EU Clinical Trials Registry, EudraCT 2011–005871-18 and ClinicalTrials.gov, NCT01604629.
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Introduction
Spondyloarthritis (SpA), a group of rheumatic diseases
that share immunogenic, clinical and radiological char-
acteristics, are classified as axial (axSpA) or peripheral
by the Assessment of Spondyloarthritis International So-
ciety (ASAS). Ankylosing spondylitis (AS) is the main
disease within SpA, with a prevalence of 0.4–0.9% in
Caucasians, and marked differences by race, prevalence
of HLA B27, and geographical area [1, 2]. Despite treat-
ment, many Patients with SpA have impaired quality of
life and work disability [3, 4]. SpA management aims to
achieve and maintain clinical remission or low disease
activity (LDA) [5]. The first step is non-steroidal
anti-inflammatory drugs (NSAIDs) and physical therapy,
although 60% of patients obtain no clinical benefit [6].
Disease-modifying anti-rheumatic drugs (DMARDs) are
not deemed efficacious, but tumour necrosis factor in-
hibitors (TNFi) can induce and sustain long-term clin-
ical remission in patients not responding to NSAIDs [7].
However, the optimal duration and dose for long-term
treatment remain unclear, and the recommended TNFi
doses are the same for treatment of acute and chronic
disease. Although the risk-benefit is favourable, pro-
longed treatment with TNFi chronically suppresses the
immune response, increasing the risk of serious infection
dose-dependently, especially in frail patients. It is un-
clear whether chronic use may increase malignancies
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and neurological demyelinating diseases [8–10]. Finally,
TNFi are expensive and a cost burden.
Discontinuation of TNFi after achieving clinical remis-
sion is followed by early relapse in most cases [11–13].
However, lower doses of TNFi may be sufficient in pa-
tients with LDA and low levels of inflammatory media-
tors, according to uncontrolled or observational studies
[14, 15]. Some clinical guidelines recommend empirical
dose reductions despite a lack of robust supportive evi-
dence [16]. Likewise, although drug-level monitoring
may help physicians optimize and prevent overtreatment
in patients with rheumatoid arthritis treated with TNFi
[17], there are no conclusive data on useful biomarkers
for the monitoring of TNFi in AS [18].
The objective of this study was to determine the suit-
ability of dose reduction for long-term treatment with
TNFi in axSpA and potential predictors of poor clinical
response. The main study hypothesis was that in patients
with axSpA in persistent clinical remission with TNFi,
reduced TNFi doses would be not inferior to full doses,
as assessed by the proportion of patients not reaching
LDA criteria for changing treatments. In addition, we
analysed pre and post withdrawal drug levels, and
markers of inflammation and bone markers in a subset.
Patients and methods
A prospective multicentre, parallel, controlled and ran-
domized open-label clinical trial was conducted at 22
Spanish centres. Patients were eligible if they met criteria
for axSpA according to the ASAS classification criteria
[19], on treatment with the recommended doses of com-
mercially available TNFi (infliximab, adalimumab, eta-
nercept or golimumab) at the time of the study, and in
sustained clinical remission defined as Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) ≤ 2, no
clinically active arthritis or enthesitis and C-reactive pro-
tein (CRP) equal to or higher than the upper limit of
normality for ≥ 6 months. Exclusion criteria were sec-
ondary SpA or predominantly peripheral arthritis, co-
morbidity interfering with the clinical assessment,
pregnancy and breast feeding. Before any study-related
procedure, patients were given comprehensive informa-
tion on the study objectives, procedures and risks, and
written informed consent was obtained from all patients.
Randomization and treatments
Eligible patients were randomized to receive either the
full recommended TNFi dose or a reduced dose accord-
ing to an agreed protocol supported by clinical practice
(Table 1). Patients were screened, and information on
previous TNFi treatment, clinical activity and other eligi-
bility criteria entered in the electronic case report form
(eCRF). Patients were automatically randomized by cen-
tral allocation according to a list generated using SAS
PROC PLAN v9.2 (SAS Institute Inc., Cary, NC, USA)
with a 1:1 assignment ratio between arms, stratifying by
prior TNFi treatment in blocks of four elements. The
randomization list was loaded to a separate module of
the eCRF so that the module automatically assigned the
lowest sequential number available within the
randomization stratum. An auditable registry of the date,
time and other variables related to stratification and
treatment assignment was kept. Patients and the study
investigators were not blinded to treatment once
assigned.
Clinical outcomes
The main clinical endpoint was the percentage of pa-
tients with LDA (BASDAI score < 4, plus physician glo-
bal assessment < 4, patient global assessment < 4 and
nocturnal axial pain < 4 as assessed on a 0–10 visual
analogue scale (VAS)) at one year. The key secondary
endpoint was the proportion of patients who remained
in clinical remission (BASDAI <= 2, physician global as-
sessment <= 2, and patient global assessment <= 2 with
serum CRP below the upper limit of normality) at 1 year.
Other secondary objectives were the usual axSpA clinical
outcomes (Ankylosing Spondylitis Disease Activity Score
(ASDAS)-CRP, ASAS response criteria, BASDAI, func-
tional assessment as measured by Bath Anklylosing
Spondylitis Functional Index (BASFI) and quality of life
as measured by Ankylosing Spondylitis Quality of Life
(ASQoL)). Relapses defined according to ASAS group,
based on pain, BASDAI and ASDAS-CRP [20] were cal-
culated a posteriori on recorded data. Adverse events,
serious adverse reactions requiring hospitalization and/
or treatment withdrawal, and serious infections requir-
ing systemic antibiotic treatment and/or hospitalization
were recorded.
Table 1 Study treatments
Anti-TNF drug Posology according to SPC Route Full-dose group Reduced-dose group
Adalimumab 40 mg every 2 weeks SC 40 mg every 2 weeks 40mg every 3 weeks
Etanercept 25–50 mg every 3–7 days SC 25 mg every 3 days or
50 mg every 7 days
50mg every 10 days
Golimumab 50 mg every month SC 50 mg every 4 weeks 50mg every 6 weeks
Infliximab 5 mg/Kg every 6–8 weeks IV 5 mg/Kg every 6–8 weeks 3 mg/Kg every 8 weeks
SPC Summary of Product Characteristics, SC subcutaneous, IV intravenous
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Blood samples for the measurement of TNFi,
anti-drug antibodies and inflammatory mediators were
collected within the 24 h before TNFi injection in 18
participating centres. The number of samples requested
were ≥ 2 per patient, separated by ≥ 90 days when feas-
ible. Samples were frozen and stored at − 80 °C until
shipment at the end of the study.
Inflammatory mediators were assayed at Laboratori de
Recerca – I3PT (Sabadell, Spain). Plasma levels of TNF
alpha, IL-6, sclerostin (SOST) and Dickkopf-related protein
1 (DKK-1) were determined using a Luminex multiplex im-
munoassay (Merck-Millipore, Darmstadt) (accuracy = 82–
97%, inter-assay and intra-assay precision = < 15% and <
10%, respectively); high-sensitivity CRP (hs-CRP) using a
Luminex immunoassay (Merck-Millipore, Darmstadt) (ac-
curacy = 93%, inter-assay and intra-assay precision = < 15%
and < 10%, respectively); plasma calprotectin levels using
Calprolab ELISA test HRP (Calpro, Lysaker) (inter-assay
and intra-assay precision < 7% and < 6%, respectively).
Drug and anti-drug antibody (ADA) levels were deter-
mined by assay at the Immunology Department – Hos-
pital La Paz (Madrid, Spain). TNFi was measured by
commercially available capture ELISA kits, (Promonitor,
Progenika, Derio, Vizcaya), with cutoff values established
using serum from 150 healthy blood donors and 100 pa-
tients with RA who were naïve to biological drugs. The
positivity threshold was mean optical density + 6 stand-
ard deviations: positive levels were infliximab > 0.035 μg/
ml, adalimumab > 0.024 μg/ml, golimumab > 0.022 μg/
ml and etanercept > 0.035 μg/ml. ADAs were assayed
only in samples with no detectable TNFi, using a
home-made, two-site (bridging) ELISA.
Visit schedule
Visits were scheduled according to routine clinical prac-
tice, although recommended intervals between visits
were 8–16 weeks [21]; a mandatory visit was required 1
year after randomization for the main assessment. Fol-
low up continued until the end of study, change in bio-
logical treatment, withdrawal of informed consent or
loss to follow up. NSAID treatment and dose modifica-
tion was permitted throughout the study and was re-
corded. The study protocol has been reported in full
elsewhere [22].
Sample size and statistical methods
The estimated proportion of patients at LDA after 1 year
of treatment with full-dose TNFi was 87% in patients
who were in stable remission for 4 months [23]. A
non-inferiority margin of 17% was established, and pro-
tection against type I error = 2.5% (unilateral) and
against type II error = 20%, being the estimated sample
size to test the non-inferiority hypothesis of the
reduced-dose strategy with respect to the full-dose
strategy of 85 patients per arm [24, 25]. The
non-inferiority (delta margin) of 17% was prospectively
set based on the consensus on clinical relevance reached
by the rheumatologists involved, who decided that a pro-
portion of patients with acceptable control < 70% after 1
year would severely discourage the use of dose reduction
[22]. To ensure the reliability of the study, the lower
confidence interval (CI) in the full-dose arm had to be >
60% to confirm non-inferiority, in order to ensure that
the control treatment had been reasonably effective [22].
A per-protocol set (PPS) for analysis was the
pre-defined primary population for this non-inferiority
study, following a conservative approach where any po-
tential differences can be maximized. The principal end-
point and the key secondary endpoints were also tested
in the full analysis set (FAS) population for sensitivity.
The principal and key secondary end-points were
assessed by estimating the between-treatment risk differ-
ences after 1 year of randomization and checking these
against the pre-defined non-inferiority margin (delta (δ))
of 17%. Rates and risk differences were estimated using
log-binomial regression including treatment and the fac-
tors used to stratify assignment. The effects of baseline
clinical and inflammatory parameters on the results were
evaluated, and the heterogeneity of the main results
checked for stratification factors. A detailed statistical
analysis plan was issued and approved on 25th Septem-
ber 2014. The statistical analysis was run in the SAS Sys-
tem (SAS Institute Inc., Cary, NC, USA) v9.2. The
detailed statistical methods have been reported else-
where [22].
Results
From 6th July 2012 to 15th May 2014, 157 patients were
screened. Due to recruitment delays and time restric-
tions on funding, recruitment was closed after 126 pa-
tients had been randomized; the last patient visit was on
10th June 2015. Figure 1 shows the number of patients
assigned to each treatment arm (FAS), lost to follow up
during the study (total of three patients) and the reasons
for exclusion from the PPS main analysis set. Baseline
participant characteristics were similar between groups
(Table 2). Although the protocol allowed inclusion of pa-
tients with axSpA, all included patients fulfilled criteria
for AS.
The main study result fulfilled the objective of
non-inferiority, with a proportion (95% CI) of patients
with LDA at one year of randomization of 83.8% (64.8–
102.7%) in the full-dose arm and 81.3% (62.8–99.8%) in
the reduced-dose arm, and absolute difference in LDA at
1 year between treatment groups of − 2.5% (95% CI of −
16.6 to 11.7%) in the pre-defined PPS population (Fig. 2a
and c). The lower bound of CI for the estimate in the
control arm was > 60%, fulfilling the pre-specified
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validation criteria. The percentage (95% CI) of patients
in clinical remission (the key secondary endpoint) at one
year of randomization was 83.7% (64.7–102.7%) in the
full-dose arm and 78.2% (59.7–96.8%) in the
reduced-dose arm, with absolute differences between
treatment groups of − 5.5% (− 20.6 to 9.7%) (p = 0.480)
(Fig. 2a and c). The sensitivity analysis in the FAS popu-
lation showed similar estimates for the differences be-
tween the two arms for the primary and key secondary
end-points (Fig. 2b and d). No significant differences
were observed between treatment arms for any of the
secondary variables (Table 3).
At least one blood sample was available from each of
55 subjects (29 in the full-dose group and 26 in the
reduced-dose group) for assessment of plasma levels of
inflammatory biomarkers and drugs (Additional file 1:
Table S1). All samples tested for TNFi levels were posi-
tive, and thus no ADA levels were determined.
Amongst clinical variables at baseline, BASFI, ASQoL
and the type of TNFi were all significantly associated with
the probability of LDA after 1 year in univariate models,
but only the type of TNFi and BASFI remained significant
in multivariate models. The treatment effect (dose group
assigned) showed no significant heterogeneity according
to the BASFI (p = 0.5244) or type of TNFi (p = 0.887), thus
suggesting that the predictive value of BASFI and type of
TNFi on the outcome is independent of the assigned dose
schedule (full dose or reduced dose) (Additional file 1:
Table S2). Considering inflammatory biomarkers and drug
plasma levels, only hs-CRP levels were higher in subjects
without LDA at 1 year (Additional file 1: Table S3). Uni-
variate models including both clinical and analytical bio-
markers had poor predictive value, with the lower CI for
the ROC AUC always < 0.62; multivariate methods were
unfeasible as no combination of factors improved the uni-
variate models (Additional file 1: Table S3).
Of the 126 randomized patients, serious and related
adverse events or infections were reported in 7/62 pa-
tients (11.3%) in the full-dose group and 2/61 (3.3%) pa-
tients in the reduced-dose group (p value = 0.164)
(Table 3). A total of 34 infections were reported by 26
subjects, among whom 15 infections were reported by
11/62 subjects (17.7%) in the full-dose group and 4 in-
fections were reported by 3/61 subjects (4.9%) in the
reduced-dose group as being at least possibly related to
treatment (Additional file 1: Table S4). Treatment was
discontinued in 6/62 (9.7%) and 13/61 patients (21.3%)
in the full-dose and reduced-dose groups, respectively (p
value = 0.086), among whom 3/62 (4.8%) in the full-dose
and 8/61 (13.1%) in the reduced-dose group had treat-
ment discontinued due to poor disease control, accord-
ing to physician judgment (p value = 0.204).
Fig. 1 Disposition of patients. FAS, full analysis; PPS, per-protocol main analysis set; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index;
CRP, C-reactive protein. *Not meeting inclusion criteria for remission (BASDAI ≤ 2 and CRP≤ upper limit of normality)
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Discussion
This trial has shown that a dose-reduction strategy may
be non-inferior to full-dose treatment in patients with
AS in persistent clinical remission with TNFi, in terms
of maintenance of LDA after 1 year. In the reduced-dose
group, less serious and related adverse events or infec-
tions were observed, but also more withdrawals due to
insufficient disease control, although not statistically
significant.
Observational studies have reported that complete
TNFi discontinuation in patients with AS is not feasible
[16] despite 60–80% of patients have LDA at 12–21
months after TNFi dose reduction [19, 26, 27]. However,
these studies were uncontrolled or retrospective and
sometimes had a small sample size, wide inclusion cri-
teria and many dose schedules, leading to substantial
heterogeneity that limited the generalizability of any
dose-reduction recommendation.
Our results show that more than 80% and 77% of pa-
tients with AS treated with TNFi had LDA or remission
at 1 year after randomization to standard or reduced-
dose schedules, respectively, in a pragmatic setting, with
high external validity. Clear correlation has been
reported in patients with AS between BASDAI, BASFI
or ASDAS-CRP and disease activity, function and
cost-effectiveness of treatments [28–30]. Our study has
shown similar results in both randomized arms for these
variables. No differences were observed between the
groups in the frequency of flares, and no substantial
changes in the proportion of NSAID treatments were
observed during follow up in either TNFi regimen. How-
ever, despite the overall small number of early study
withdrawals due to poor disease control, these were nu-
merically higher in the reduced-dose group. This obser-
vation has to be interpreted in the context of an
open-label study, and considering which the clinical op-
tions were in the case of observing worse clinical scores:
in the reduced-dose arm, the options included returning
to full-dose schedule, while in the full-dose group the
options were more aggressive, either dose intensification
or switching.
Since there are no universally accepted criteria for re-
mission in AS, we used strict criteria at baseline, and ran-
domized only patients with persistent and maintained
clinical remission during the last 6 months while on TNFi
[31]. In the absence of an alternative internationally agreed
Table 2 Baseline characteristics of patients













Gender (male), n (%) 53 (88.3) 49 (81.7) 102 (85.0) 48 (87.3) 47 (81.0) 95 (84.1)
Age (years), mean (SD) 46.2 (13.7) 43.7 (12.4) 44.9 (13.1) 47.2 (13.6) 43.6 (12.4) 45.6 (13.0)
BMI, mean (SD) 25.9 (3.4) 25.8 (3.8) 25.9 (3.6) 25.8 (3.4) 25.9 (3.8) 25.9 (3.6)
Years from diagnosis, median (P25, P75) 10.4 (7.1, 20.8) 9.3 (5.2, 17.6) 10.0 (5.9, 19.8) 10.4 (7.1, 22.6) 9.3 (5.0, 19.0) 10.0 (5.9, 20.3)
ASAS criteria for sacroilitis, n (%) 58 (96.7) 59 (98.3) 117 (97.5) 53 (96.4) 57 (98.3) 110 (97.3)
ASDAS-CRP, median (P25, P75) 0.7 (0.5, 1.1) 0.7 (0.5, 1.1) 0.7 (0.5, 1.1) 1.1 (0.8, 3.5) 1.0 (0.7, 1.9) 1.1 (0.7, 2.0)
BASDAI, median (P25, P75) 1.0 (0.6, 1.7) 1.0 (0.2, 1.4) 1.0 (0.4, 1.6) 1.0 (0.6, 1.7) 1.0 (0.2, 1.4) 1.0 (0.4, 1.6)
VAS nocturnal axial pain, mean (SD) 0.85 (1.0) 1.03 (1.16) 0.94 (1.09) 0.84 (1.01) 1.02 (1.15) 0.93 (1.08)
IGA, median (P25, P75) 1.0 (0.0, 2.0) 1.0 (0.0, 1.0) 1.0 (0.0, 1.0) 1.0 (0.0, 2.0) 1.0 (0.0, 1.0) 1.0 (0.0, 1.0)
PGA, median (P25, P75) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 1.0) 1.0 (0.0, 1.0)
Current TNFi, n (%)
Adalimumab 24 (40.0) 23 (38.3) 47 (39.2) 22 (40.0) 22 (37.9) 44 (38.9)
Etanercept 21 (35.0) 20 (33.3) 41 (34.2) 19 (34.5) 19 (32.8) 38 (33.6)
Golimumab 4 (6.7) 5 (8.3) 9 (7.5) 4 (7.3) 5 (8.6) 9 (8.0)
Infliximab 11 (18.3) 12 (20.0) 23 (19.2) 10 (18.2) 12 (20.7) 22 (19.5)
N of previous TNFi, n (%)
None 50 (83.3) 44 (73.3) 94 (78.3) 46 (83.6) 42 (72.41) 88 (77.9)
One 10 (16.7) 11 (18.3) 21 (17.5) 9 (16.4) 11 (19.0) 20 (17.7)
Two 0 (0.0) 5 (8.3) 5 (4.2) 0 (0.0) 5 (8.6) 5 (4.4)
NSAID use, n (%) 16 (26.7) 14 (23.3) 28 (24.8) 15 (27.3) 13 (22.4) 28 (24.8)
n number, SD standard deviation, P25 percentile 25, P75 percentile 75, BMI body mass index, ASAS Assessment of Spondyloarthritis International Society, ASDAS-
CRP Ankylosing Spondylitis Disease Activity Score including C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index; VAS patient’s rating of
nocturnal axial pain by visual analogue scale ranging from 0 (none) to 10 (worst), PGA Patient Global Assessment of disease activity rated from 0 (best) to 10
(worst), IGA Investigator’s Global Assessment of disease activity rated from 0 (best) to 10 (worst), TNFi TNF inhibitor, NSAID non-steroidal anti-inflammatory drug
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consensus on thresholds for response and control at the
time of the study design, we used the Spanish Society of
Rheumatology definition for low disease activity [16]. The
definition was reflective of a consensus on the clinical
therapeutic goal of treatment requiring action if not met.
The definition was well-known, widely accepted and ap-
plied in clinical practice by rheumatologists in Spain.
The standardized dose-reduction protocol included
lengthening the dosing interval by 50% for all subcutane-
ous TNFi and reducing the infliximab dose from 5 to 3
mg/8 week, according to reported data [15]. This
allowed a reduction in the heterogeneity of drug re-
gimes, a limitation reported by other studies [27], al-
though it did not allow evaluation of the potential
benefit of additional patient-tailored dose reductions.
Most patients were on etanercept and adalimumab, with
< 20% of patients on infliximab, consistent with previous
reports [12]. Randomization was stratified by drug to en-
sure comparability of groups; subgroup analysis based
on stratification factors suggested that infliximab was as-
sociated with a higher risk of failure, although no inter-
action with the randomized strategy was observed, and
thus the risk was similar regardless of whether doses
were reduced or not. Considering that patients were not
randomized to a given TNFi, but to the dosing strategy,
this observation is of limited value for causality assess-
ment, and indication bias cannot be discarded. Similarly,
although observational data suggest that dose reduction
may be easier with etanercept [14], we found no differ-
ences for this stratum.
Fig. 2 Proportion of patients with low disease activity and clinical remission at 12 months. a Proportion of subjects with low disease activity
and clinical remission at 12 months, per-protocol subset (main analysis). b Proportion of subjects with low disease activity and clinical
remission at 12 months, intention-to-treat subset. c Adjusted differences between groups and non-inferiority testing for low disease activity
and clinical remission, per-protocol subset (main analysis). d Adjusted differences between groups and non-inferiority testing for low disease
activity and clinical remission, intention-to-treat subset. Low disease activity was defined by Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) < 4 and Physician Global Assessment < 4, Patient Global Assessment < 4 and axial pain at night < 4. Clinical remission was defined by
BASDAI ≤ 2, Physician Global Assessment ≤ 2 and Patient Global Assessment ≤ 2
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One goal of personalized medicine is to identify probable
beneficiaries of an intervention through clinical or bio-
logical markers [18]. We attempted to identify clinical and
biological markers of a successful TNFi dose-reduction
strategy. Baseline values of BASFI, ASQoL and the TNFi
drug were associated with the odds of LDA after 1 year in
univariate models; but in multivariate models only TNFi
drug and BASFI remained significant. Similarly, hs-CRP
was higher in subjects without LDA at 1 year. CRP best re-
flects objective inflammation and serum CRP is predictive
of TNFi response in patients with AS [30].
Although reports have suggested no advantages of
hs-CRP as compared with CRP in predicting the clinical
response to TNFi [18], the results observed for hs-CRP
are not unexpected, since it is a more sensitive tech-
nique. Reports have suggested a potential association
with TNFi levels in rheumatoid arthritis, but data on AS
are controversial [31–33]. We found no association be-
tween serum TNFi concentrations and the persistence of
LDA at 1 year, although we had only few samples and
these were for heterogeneous drugs. All samples had
quantifiable TNFi levels, so none of the samples was
tested for ADA. Other biomarkers, including calprotec-
tin, did not significantly predict the likelihood of LDA at
1 year in our study. Recently, calprotectin levels have
been suggested as a predictor of the clinical response
[18], although in acute clinical response, and not in pa-
tients in remission.
Table 3 Secondary endpoints
Efficacy secondary variables at 1 year
Variables Full dose (n = 55) Dose reduction (n = 58) Differences between groups P value
ASDAS-CRP < 1.3a 61.4% [47.3%; 75.5%] 53.5% [39.7%; 67.3%] 7.8% [−10.0%; 25.8%] 0.389
ASDAS-CRP relapsea 6.6% [−5.4%; 18.7%] 12.7% [1.4%; 24.0%] −6.1% [−25.2%; 12.9%] 0.529
Relapse BASDAI-VASa 15.9% [−3.1%; 34.9%] 10.4% [−9.1%; 29.8%] 5.5% [−12.3%; 23.4%] 0.545
Relapse SERa 6.4% [−13.0%; 25.8%] 10.1% [−7.9%; 28.1%] − 3.7% [− 19.2%; 11.8%] 0.638
NSAIDs usea 18.3% [− 1.2%; 37.7%] 20.6% [1.5%; 39.8%] −2.4% [− 18.9%; 14.2%] 0.779
ASDAS-CRP scoreb 1.1 (0.1) [0.9;1.3] 1.1 (0.1) [0.9;1.3] 0.0 (0.2) [−0.3;0.3] 0.783
BASDAIb 1.4 (0.2) [1.1;1.7] 1.4 (0.2) [1.1;1.7] − 0.0 (0.2) [− 0.5;0.4] 0.890
VAS night axial painb 1.4 (0.2) [1.0;1.8] 1.1 (0.2) [0.7;1.6] 0.3 (0.3) [−0.3;0.9] 0.337
PGAb 1.6 (0.2) [1.2;2.0] 1.6 (0.2) [1.1;2.0] 0.0 (0.3) [−0.6;0.6] 0.962
IGAb 1.1 (0.2) [0.8;1.4] 1.1 (0.2) [0.8;1.4] −0.0 (0.2) [− 0.4;0.40] 0.923
BASFIb 1.7 (0.2) [1.2;2.1] 1.8 (0.2) [1.3;2.3] −0.2 (0.3) [− 0.8;0.5] 0.616
ASQoLb 2.3 (0.5) [1.2;3.3] 2.2 (0.6) [1.0;3.3] 0.1 (0.7) [−1.3;1.5] 0.858
Safety secondary variables
Adverse event or infections Full dose (n = 62) Dose reduction (n = 61) Differences between groups P value
Anyc 22 (35.5%) [23.6%;47.4%] 17 (27.9%) [16.6%;39.1%] (7.6%) [−8.8%;24.0%] 0.439
Relatedc 8 (12.9%) [4.6%;21.2%] 5 (8.2%) [1.3%;15.1%] (4.7%) [−6.1%;15.5%] 0.559
Severec 14 (22.6%) [12.2%;33.0%] 11 (18.0%) [8.4%;27.7%] (4.6%) [−9.6%;18.7%] 0.655
Severe and relatedc 7 (11.3%) [3.4%;19.2%] 2 (3.3%) [−1.2%;7.7%] (8%) [− 1.1%;17.1%] 0.164
Ankylosing Spondylitis Disease Activity Score including C-reactive protein (ASDAS-CRP) relapse was defined by increase ≥ 1.1. Bath Ankylosing Spondylitis Disease
Activity Index-visual analogue scale (BASDAI-VAS) was defined by increases of 20% or a 2-unit increase in the 0–10 scale. SER relapse was defined by BASDAI ≥ 4,
global clinical assessment by physician ≥ 4 and at least one of three following criteria: patient assessment ≥ 4, axial nocturnal pain (VAS) ≥ 4, and increase in acute
phase reactants (reactive °C protein (PCR) and/or erythrocyte sedimentation rate (ESR). Ankylosing Spondylitis Disease Activity Score-C reactive protein (ASDAS-C),
which is calculated as (0.12 x back pain) + (0.06 x duration of morning stiffness) + (0.11 x patient GA) + (0.07 x peripheral pain/swelling) + (0.58 x Ln(CRP + 1)); if
CRP is not available but ESR is available, the last term is changed by (0.29 x √(ESR)). BASDAI is calculated as {A + B + C + D+ [(E + F)/2]}/5 where A to E are 6 VAS,
rated 0 (best) to 10 (worst) assessing (A) fatigue, (B) axial skeletal pain, (C) peripheral joint pain, (D) pain on contact or pressure, (E) intensity of morning stiffness
and (F) duration of morning stiffness; VAS nocturnal axial pain is the patient’s rating of nocturnal pain by VAS ranging from 0 (none) to 10 (worst). Patient Global
Assessment (PGA) of disease activity was rated from 0 (best) to 10 (worst). Investigator’s Global Assessment (IGA) of disease activity was rated from 0 (best) to 10
(worst). The Bath Ankylosing Spondylitis Functional Index (BASFI) is calculated as the average value of answers to 10 questions rated from 0 (best) to 10 (worst).
Ankylosing Spondylitis Quality of Life (ASQoL - Spanish validated version) scores from 0 to 18, where lower scores indicate better health-related quality of life.
Adverse event (AE) or infection presented as proportion (95% CI) of patients with at least one reported adverse event and/or infection; related presented as
proportion (95% CI) of patients with at least one reported AE and/or infection assessed by the investigator as at least possibly related to TNF inhibitor (TNFi)
treatment; severe presented as proportion (95% CI) of patients with at least one severe reported AE and/or infection according to standard definitions (fatal or
life-threatening, required or prolonged the patient’s hospitalization, caused significant or persistent disability, caused congenital anomaly/birth defect or required
immediate medical intervention to avoid any of the previous outcomes); severe and related presented as proportion (95% CI) of patients with at least one
reported severe and related AE and/or infection. SER: Spanish Society of Rheumatology (Sociedad Española de Reumatología)
aAdjusted percentage estimates [95% CI], binomial regression
bAdjusted least square means (standard error of the mean) [95% CI], mixed model for repeated measurements cNumber (%) [95CI]), analyzed by Fisher’s exact test
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There were no interactions between dose regimen and
TNFi or BASFI, indicating that their predictive value was
independent of the actual dose regimen assigned, and
multivariate models including biological markers were of
low predictive value. Thus, we could not propose any
marker to identify patients with higher chances of main-
taining a low disease activity after reduction of TNFi dose.
Serious adverse events and infections were nominally
less than one third in the reduced-dose group as com-
pared to full dose, although not significant. This suggests
low TNFi doses might have a better safety profile, but
confirmation is needed, since the size and duration of
our study were insufficient to draw conclusions. How-
ever, the differences might be relevant, especially since
these are long-term treatments for often-fragile patients.
Our study has several limitations. First, due to limited
funding and recruitment delays, the final sample size
was smaller than anticipated. Although the sample was
sufficient to conclude on the pre-determined primary
objective, the limited sample size hindered the imple-
mentation of secondary objectives. Differences in ad-
verse events were not significant and biological samples
were obtained from only half the study population, likely
reducing the ability to build a predictive model to iden-
tify patients with poorer chances of maintaining LDA
after dose-halving. In addition, although the study was
designed to include axSpA, only patients with AS were
finally included. In addition, the study was not designed
to determine which TNFi is more effective, nor powered
to determine whether a specific TNFi can be reduced
more successfully than another.
A conservative TNFi reduction schedule was applied
in this study (about 50% of the recommended dose), and
neither the potential benefit of an extra dose reduction
or the effects of treatment withdrawal were studied. In
clinical practice, infliximab can be reduced more than
other TNFi, i.e., dose and interval; however, given the
limited statistical power and the fact that this was an un-
planned analysis, we cannot venture to show results of
subgroup analysis by dose. Likewise, the 12-month fol-
low up was insufficient to determine the potential effects
of long-term TNFi reduction, especially on structural
damage, which requires 2–4 years to detect relevant
changes [31, 34]. A suggestion that TNFi dose tapering
may be associated with more rapid radiographic progres-
sion than full doses regardless of LDA maintenance [31],
especially in patients with baseline syndesmophytes,
must be confirmed by prospective studies. Strict moni-
toring of radiographic progression of patients with AS is
recommended if dose reduction is considered [31].
Conclusion
In spite of a number of limitations, this is the first
randomized trial to support the non-inferiority of
reduced-dose TNFi doses compared with full doses in pa-
tients with SpA. The results were consistent across many
variables and TNFi drugs, and suggest a better safety pro-
file with reduced doses, although the safety data must be
interpreted with caution due to the small sample size.
Overall, the study results support TNFi dose-reduction in
patients with AS in stable clinical remission.
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